Key Albumin Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
The worldwide market is vigorously gaining increased exposure with the presence of leading organizations, including Takeda, Grifols, and CSL Behring, collectively controlling the market with a combined share. These players have readily implemented strategies, such as biopharmaceutical partnerships and collaboration, research and development activities for recombinant albumin, plasma self-sufficiency, and market penetration. For instance, Seqirus and Baxter successfully partnered with each other to supply albumin for mRNA vaccine stabilizers. Likewise, LFB Group and Takeda initiated an investment for yeast-based alternatives to albumin, thereby creating a positive influence on the overall market.
Here is a list of key players operating in the market:
|
Company Name (Country) |
Industry Focus |
Market Share (2025) |
|
CSL Behring (U.S.) |
Plasma-derived albumin, recombinant albumin for therapeutics & biopharma |
18.8% |
|
Grifols (Spain) |
Human serum albumin (HSA) for critical care & diagnostics |
15.9% |
|
Takeda Pharmaceuticals (U.S.) |
Plasma fractionation, albumin for burns & liver disease |
13.3% |
|
Octapharma (Switzerland) |
Liquid & lyophilized albumin, focus on ICU and emergency medicine |
10.8% |
|
Baxter International (U.S.) |
Albumin solutions for surgeries & hypoalbuminemia |
9.3% |
|
Kedrion Biopharma (Italy) |
Plasma-derived albumin, specialized in pediatric and geriatric applications |
xx% |
|
Biotest (Germany) |
HSA for biopharmaceutical excipients and clinical use |
xx% |
|
LFB Group (France) |
Recombinant albumin for vaccines & monoclonal antibodies |
xx% |
|
Sanquin (Netherlands) |
Non-profit plasma collector, supplies albumin to EU hospitals |
xx% |
|
Bio Products Laboratory (UK) |
Albumin for rare diseases and trauma care |
xx% |
|
SK Plasma (South Korea) |
Emerging leader in Asian plasma-derived albumin |
xx% |
|
Biological E. Ltd. (India) |
Low-cost albumin for emerging markets, focus on India & Southeast Asia |
xx% |
|
Serum Institute of India |
Affordable albumin for LMICs, partnerships with WHO |
xx% |
|
Protheragen (Malaysia) |
Contract manufacturing of albumin for biopharma |
xx% |
|
Seqirus (Australia) |
Albumin as stabilizer for vaccines (e.g., influenza) |
xx% |
Sources: NLM, NIH, WHO, CDC, HRSA
Below are the areas covered for each company in the market:
